Tianjin Dev (00882.HK): Tianjin Lisheng Pharmaceutical's net income in the first half of the year was 0.102 billion yuan, a year-on-year increase of 13.50%.

Gelonghui Finance · Aug 23, 2024 06:18

Tianjin Development (00882.HK) announced that Tianjin Lisheng Pharmaceutical (002393.SZ) achieved revenue of 0.745 billion yuan (RMB) in the first half of 2024, a year-on-year growth of 13.25%; the net income attributable to Lisheng Pharmaceutical shareholders was 0.102 billion yuan, a year-on-year growth of 13.50%; the basic earnings per share was 0.40 yuan.

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

天津发展(00882.HK)：力生制药上半年净利润1.02亿元 同比增长13.50%

Tianjin Dev (00882.HK): Tianjin Lisheng Pharmaceutical's net income in the first half of the year was 0.102 billion yuan, a year-on-year increase of 13.50%.

Risk Disclaimer

Statement

天津发展(00882.HK)：力生制药上半年净利润1.02亿元同比增长13.50%